Back to top

gene-editing: Archive

Zacks Equity Research

bluebird (BLUE) Up 101% in the Past Three Months: Here's Why

bluebird bio (BLUE) has surged in the past three months owing to its pipeline development. The company's lead candidate recently received FDA approval as a potential treatment for beta-thalassemia.

RYTMPositive Net Change PLRXPositive Net Change